Trading Update: TG Therapeutics Inc (TGTX) Stock Endures 5.53% Monthly Volatility


The stock of TG Therapeutics Inc (TGTX) has seen a 2.25% increase in the past week, with a 25.09% gain in the past month, and a 21.14% flourish in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are at 5.53% for TGTX. The simple moving average for the past 20 days is 1.75% for TGTX’s stock, with a 25.50% simple moving average for the past 200 days.

Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?

TG Therapeutics Inc (NASDAQ: TGTX) has a higher price-to-earnings ratio of 76.42x compared to its average ratio, The 36-month beta value for TGTX is at 2.31. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for TGTX is 137.79M, and currently, shorts hold a 24.89% of that float. The average trading volume for TGTX on May 29, 2024 was 3.66M shares.

TGTX) stock’s latest price update

The stock of TG Therapeutics Inc (NASDAQ: TGTX) has increased by 0.84 when compared to last closing price of 16.71.Despite this, the company has seen a gain of 2.25% in its stock price over the last five trading days. reported 2024-05-28 that NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CMSC meeting website at or by clicking on the following link: Details for the upcoming BRIUMVI presentations are outlined below.

Analysts’ Opinion of TGTX

Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the previous year 2023.

Jefferies, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $40, previously predicting the price at $55. The rating they have provided for TGTX stocks is “Buy” according to the report published on June 26th, 2023.

BofA Securities gave a rating of “Underperform” to TGTX, setting the target price at $5 in the report published on May 20th of the previous year.

TGTX Trading at 9.34% from the 50-Day Moving Average

After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.53% of loss for the given period.

Volatility was left at 5.53%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +26.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.71% upper at present.

During the last 5 trading sessions, TGTX rose by +2.25%, which changed the moving average for the period of 200-days by +73.71% in comparison to the 20-day moving average, which settled at $16.74. In addition, TG Therapeutics Inc saw -1.35% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 5,000 shares at the price of $15.94 back on Mar 13 ’24. After this action, Lonial Sagar now owns 108,878 shares of TG Therapeutics Inc, valued at $79,675 using the latest closing price.

Charney Laurence N, the Director of TG Therapeutics Inc, sale 22,000 shares at $15.97 during a trade that took place back on Mar 12 ’24, which means that Charney Laurence N is holding 215,229 shares at $351,340 based on the most recent closing price.

Stock Fundamentals for TGTX

Current profitability levels for the company are sitting at:

  • 0.17 for the present operating margin
  • 0.93 for the gross margin

The net margin for TG Therapeutics Inc stands at 0.14. The total capital return value is set at 0.18. Equity return is now at value 43.93, with 14.44 for asset returns.

Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 4.01.

Currently, EBITDA for the company is 21.06 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 9.13. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.


In conclusion, TG Therapeutics Inc (TGTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts